Literature DB >> 29354767

Impact of direct-acting antiviral agents on the risk for hepatocellular carcinoma.

Xavier Adhoute1, Paul Castellani1, Marc Bourlière1.   

Abstract

Entities:  

Year:  2017        PMID： 29354767      PMCID： PMC5762991          DOI： 10.21037/tgh.2017.12.04

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN： 2415-1289


× No keyword cloud information.
  19 in total

1.  Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy: Issue of the interval between HCC treatment and antiviral therapy.

Authors:  Pei-Chien Tsai; Chung-Feng Huang; Ming-Lung Yu
Journal:  J Hepatol       Date:  2016-11-10       Impact factor: 25.083

Review 2.  Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression.

Authors:  Reem Waziry; Behzad Hajarizadeh; Jason Grebely; Janaki Amin; Matthew Law; Mark Danta; Jacob George; Gregory J Dore
Journal:  J Hepatol       Date:  2017-08-09       Impact factor: 25.083

3.  High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis.

Authors:  Helder Cardoso; Ana Maria Vale; Susana Rodrigues; Regina Gonçalves; Andreia Albuquerque; Pedro Pereira; Susana Lopes; Marco Silva; Patrícia Andrade; Rui Morais; Rosa Coelho; Guilherme Macedo
Journal:  J Hepatol       Date:  2016-07-29       Impact factor: 25.083

4.  Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma.

Authors:  Ju Dong Yang; Bashar A Aqel; Surakit Pungpapong; Gregory J Gores; Lewis R Roberts; Michael D Leise
Journal:  J Hepatol       Date:  2016-07-05       Impact factor: 25.083

5.  Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment.

Authors:  Karin Kozbial; Stephan Moser; Remy Schwarzer; Hermann Laferl; Ramona Al-Zoairy; Rudolf Stauber; Albert F Stättermayer; Sandra Beinhardt; Ivo Graziadei; Clarissa Freissmuth; Andreas Maieron; Michael Gschwantler; Michael Strasser; Markus Peck-Radosalvjevic; Michael Trauner; Harald Hofer; Peter Ferenci
Journal:  J Hepatol       Date:  2016-06-16       Impact factor: 25.083

6.  Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy.

Authors:  María Reig; Zoe Mariño; Christie Perelló; Mercedes Iñarrairaegui; Andrea Ribeiro; Sabela Lens; Alba Díaz; Ramón Vilana; Anna Darnell; María Varela; Bruno Sangro; José Luis Calleja; Xavier Forns; Jordi Bruix
Journal:  J Hepatol       Date:  2016-04-13       Impact factor: 25.083

7.  Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents.

Authors:  Fasiha Kanwal; Jennifer Kramer; Steven M Asch; Maneerat Chayanupatkul; Yumei Cao; Hashem B El-Serag
Journal:  Gastroenterology       Date:  2017-06-19       Impact factor: 22.682

8.  Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy.

Authors:  Hiroshi Imamura; Yutaka Matsuyama; Eiji Tanaka; Takao Ohkubo; Kiyoshi Hasegawa; Shinichi Miyagawa; Yasuhiko Sugawara; Masami Minagawa; Tadatoshi Takayama; Seiji Kawasaki; Masatoshi Makuuchi
Journal:  J Hepatol       Date:  2003-02       Impact factor: 25.083

9.  Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.

Authors:  Nezam Afdhal; Stefan Zeuzem; Paul Kwo; Mario Chojkier; Norman Gitlin; Massimo Puoti; Manuel Romero-Gomez; Jean-Pierre Zarski; Kosh Agarwal; Peter Buggisch; Graham R Foster; Norbert Bräu; Maria Buti; Ira M Jacobson; G Mani Subramanian; Xiao Ding; Hongmei Mo; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Alessandra Mangia; Patrick Marcellin
Journal:  N Engl J Med       Date:  2014-04-11       Impact factor: 91.245

10.  Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts.

Authors: 
Journal:  J Hepatol       Date:  2016-06-07       Impact factor: 25.083
View more
  2 in total

1.  No evidence for higher rates of hepatocellular carcinoma after direct-acting antiviral treatment: a meta-analysis.

Authors:  Stephanie M Rutledge; Hui Zheng; Darrick K Li; Raymond T Chung
Journal:  Hepatoma Res       Date:  2019-08-07

Review 2.  Expansion of the hepatocellular carcinoma Milan criteria in liver transplantation: Future directions.

Authors:  Mihai-Calin Pavel; Josep Fuster
Journal:  World J Gastroenterol       Date:  2018-08-28       Impact factor: 5.742
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.